This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Theravance's NDA for COPD Candidate Gets FDA Acceptance
by Debapriya Chakraborty
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin
by Zacks Equity Research
Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.
Theravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
by Zacks Equity Research
Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.
Theravance/Mylan Presents Phase III Data on COPD Candidate
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) and partner Mylan recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key pipeline candidate, revefenacin (TD-4208).
Theravance (TBPH) Up 17.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.
Theravance's Infection Drug Vibativ Positive in TOUR Study
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) recently released positive interim data from the ongoing TOURstudy evaluating how Vibativ (telavancin) is used to treat patients with bacteremia or infective endocarditis (IE).
The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ELEMENTS SPECTRUM Large Cap U.S. Sector Momentum Index ETN, Advanced Micro Devices, AK Steel Holdings, Theravance Biopharma and Fairmount Santrol Holdings
Santa on Way to Take Over Trump Rally? ETFs & Stocks to Buy
by Sweta Killa
Given the encouraging macro trends and investors' increased appetite for riskier assets, Santa seems to be coming to the stock market this year.
Theravance Stock Up on Fast Track Status for Velusetrag
by Zacks Equity Research
Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.